Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Incyte Corp

NASDAQ: INCY · Industrial Applications and Services · 6 alerts · CIK 879169

Share price
$120.27Close, Nov 16
Market cap
$24.5B
Shares outstanding
203.83MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Commercial Physical & Biological ResearchSIC 8731

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Incyte Corp filings on SEC EDGAR ↗

4:09 PM ET 8-K
Business Update

Incyte Business Update

Incyte Corporation has decided not to proceed with its planned Phase 3 MAESTRA-3 study of INCB123667 in combination with bevacizumab for ovarian cancer. The decision was based on internal portfolio prioritization rather than safety or efficacy concerns and is not expected to impact the company's financial guidance.

4:08 PM ET Form 4
Insider Selling

Incyte CMO & Head of Late-Stage Dev. Steven H. Stein Sells $28.4M of Stock

Steven H. Stein, CMO & Head of Late-Stage Dev., sold 240,193 shares of Incyte Corp at $116.06 to $119.66 a share (average $118.39) in 5 transactions, worth $28.4M in total on Nov 6, 2026. Shares held after the trade: 30,916 (-61.1%).

Value
$28.4M
Shares
240,193
Average price
$118.39
Role
CMO & Head of Late-Stage Dev.
Holding change
-61.1%
Trade date
Nov 6, 2026
4:09 PM ET Form 4
Insider Selling

Incyte Principal Accounting Officer Thomas Tray Sells $72.6K of Stock

Thomas Tray, Principal Accounting Officer, sold 610 shares of Incyte Corp at $118.96 a share, worth $72.6K in total on Nov 3, 2026. Shares held after the trade: 21,126 (-2.8%).

Value
$72.6K
Shares
610
Price
$118.96
Role
Principal Accounting Officer
Holding change
-2.8%
Trade date
Nov 3, 2026
4:04 PM ET 10-Q
Financial Results

Incyte Q3 2026 Results: Net Loss of $785M

Incyte Corporation reported total revenues of $4.5 billion for the nine months ended September 30, 2026, a significant increase from $3.6 billion in the prior year. However, the company recorded a net loss of $784.8 million for the third quarter of 2026, primarily driven by a substantial increase in research and development expenses to $1.79 billion.

Key figure
Net loss $785M
7:04 AM ET 8-K
Financial Results

Incyte Financial Results

Incyte reported third quarter 2026 total revenue of $1.56 billion, a 14% year-over-year increase driven by strong sales of Jakafi ($827M) and Opzelura ($255M). The company raised its full-year 2026 financial guidance for total net sales and key product portfolios. Results were impacted by a one-time $1.23 billion R&D expense related to the acquisition of Vega Therapeutics.

Term
Q3 2026

“Our third quarter was marked by strong commercial performance, meaningful pipeline progress and important regulatory achievements. Net sales growth was strong in both the U.S. and internationally, creating a durable core business beyond Jakafi.”

Bill Meury, Chief Executive Officer, Incyte
4:38 PM ET Form 4
Insider Selling

Incyte President, Global Head of R&D Pablo J. Cagnoni Sells $298K of Stock

Pablo J. Cagnoni, President, Global Head of R&D, sold 2,642 shares of Incyte Corp at $112.71 a share, worth $298K in total on Oct 15, 2026. Shares held after the trade: 183,200 (-1.4%).

Value
$298K
Shares
2,642
Price
$112.71
Role
President, Global Head of R&D
Holding change
-1.4%
Trade date
Oct 15, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.